Abstract:Objective A meta-analysis of randomised controlled trials on the efficacy and safety in patients with Gram-positive cocci infections treated with linezolid versus with vancomycin.Methods The data were collected from the MEDLINE,EMBASE,OVID,the Cochrane library,and CNKI.We also handsearched relevant journals.Randomized controlled trials comparing linezolid with vancomycin in patients with Gram-positive cocci infections were eligible for inclusion.Two investigators independently assessed the quality and extracted the data.The methodological quality of trails was assessed by the Jadad-scale plus allocation concealment.Heterogeneity was examined by chi-square test.Fixed effects model or random effects model were used to pool the data.Sensitivity analyses were used in the treatment course.Results Twelve randomized controlled studies comparing linezolid with vancomycin were analyzed,focusing on the 5,863 patients with Gram-positive cocci infections.It was found by meta-analysis that,with respect to clinical treatment success,linezolid was more effective than vancomycin in clinically evaluation patients at the end-of-treatment visit [OR 1.98,95%CI(1.32,2.98),P=0.001] and at the test-of-cure visit [OR 1.34,95%CI(1.01,1.76),P=0.04],and there was more effective than vancomycin in intention-to-treat patients at the test-of-cure visit [OR 1.20,95%CI(1.01,1.43),P=0.04].With respect to microbiological treatment success,linezolid was more effective than vancomycin in microbiologically evaluation patients at the test-of-cure visit [OR 1.39,95%CI(1.12,1.73),P=0.003].Additionally,empirical treatment with linezolid was associated with increased eradication rates for S.aureus strains [OR=1.84,95%CI(1.39,2.42),P<0.0001] and enterococcal species [OR=5.42,95%CI(1.49,19.71),P=0.01] in comparison with vancomycin in microbiologically evaluation patients at the test-of-cure visit.But,there was no difference in eradication rates for MRSA strains [OR=1.54,95%CI(0.97,2.45),P=0.07],Streptococcal species [OR=0.89,95%CI(0.31,2.54),P=0.82].Mortality was similar between the groups [OR=1.07,95%CI(0.89,1.28),P=0.50].Treatment with linezolid was not associated with more adverse effects in general in comparison with vancomycin [OR=1.10,95%CI(0.83,1.44),P=0.52].Conclusion Linezolid is more effective than vancomycin for treatment of patients with Gram-positive cocci infections although rigorously designed large sample size randomized double blind clinical trials are required to further demonstrate and support the conclusion.

Efficacy and Safety of Teicoplanin on Treatment of Pulmonary Tuberculosis Combined with Gram-Positive Cocci Infection in Lungs

Multicenter Randomized Controlled Clinical Trial on Teicoplanin Versus Vancomycin

Teicoplanin and Vancomycin Treatment in Patients with Lung Infection of MRSA:A Clinical Evaluation

[Clinical Study of Teicoplanin in the Treatment of Patients with Gram-Positive Cocci: the Chinese Experience].

Efficacy of teicoplanin in treatment of Gram-positive coccal lower respiratory tract infection among elderly patients.

Effect of Piperacillin/tazobactam on Treating Traumatic Brain Injury with Pulmonary Infection: a Clinical Observation

Glycopeptides Antibiotics Teicoplanin in Elder Patients with Lung Infection Due to MRSA:Evaluation of Efficacy and Safety

Efficacy of Teicoplanin in Bloodstream Infections Caused by Enterococcus Faecium: Posthoc Analysis of a Nationwide Surveillance

Treatment of Teicoplanin for Severe Brain Injury Complicated with Nosocomial Pneumonia.

Teicoplanin as an Effective Alternative to Vancomycin for Treatment of MRSA Infection in Chinese Population: A Meta-analysis of Randomized Controlled Trials

The Study of the Effect of the Treatment of Multi-Drug Resistent Pulmonary Tuberculosis with with Steam Inhalations and Chemotherapy

Factors On Trough Teicoplanin Levels, Associations Between Levels, Efficacy And Safety In Patients With Gram-Positive Infections

Evaluation of the Antibacterial Effect in Vitro of Moxifloxacin and Linezolid on Nontuberculous Mycobacterium.

A controlled clinical study of long course chemotherapy regimens combined with immunopotentiator in the treatment of multi-drug resistant pulmonary tuberculosis

Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis

[A Study on the Clinical Efficacy of a Combination Regimen with Levofloxacin and Capreomycin in the Treatment of Multi-Drug Resistant Pulmonary Tuberculosis].

Surveillance of Bacterial Resistance in Gram-positive Cocci

Effects of Moxifloxacin Combined with Capreomycin on Clearance Rate of Sputum Bacteria and Immunity Function Pulmonary Tuberculosis Patients with Multi-Drug Resistance

Linezolid vs vancomycin for the treatment of Gram-positive cocci infections in intensive care uhit patients:meta-analysis for randomized controlled trials

Linezolid versus vancomycin for treatment of Gram-positive cocci infections:Meta-analysis of randomised controlled trials

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.